Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth

被引:0
|
作者
Markus Loeffler
Gaelle Le’Negrate
Maryla Krajewska
John C. Reed
机构
[1] Burnham Institute for Medical Research,
来源
Cancer Immunology, Immunotherapy | 2009年 / 58卷
关键词
CCL21; Cancer therapy; Bacterial therapy; Tumor targeting;
D O I
暂无
中图分类号
学科分类号
摘要
Intravenously-applied bacteria tend to accumulate in tumors and can sporadically lead to tumor regression. Systemic administration of attenuated Salmonella typhimurium is safe and has shown no significant adverse effects in humans. The purpose of this study was to test the hypothesis that engineering S. typhimurium to express a chemokine, CCL21, would increase anti-tumor activity. We engineered an attenuated strain of S. typhimurium to produce the chemokine CCL21. Attenuated S. typhimurium expressing CCL21 significantly inhibited the growth of primary tumors and pulmonary metastases in preclinical models of multi-drug-resistant murine carcinomas, while control bacteria did not. Histological analysis of tumors showed marked inflammatory cell infiltrates in mice treated with CCL21-expressing but not control bacteria. Levels of cytokines and chemokines known to be induced by CCL21 [e.g., interferon-γ (INFγ), CXCL9, and CXCL10] were significantly elevated in tumors of mice treated with CCL21-expressing but not control S. typhimurium. The anti-tumor activity was found to be dependent on CD4- and CD8-expressing cells, based on antibody-mediated in vivo immuno-depletion experiments. Anti-tumor activity was achieved without evidence of toxicity. In summary, chemokine-expressing, attenuated bacteria may provide a novel approach to cancer immunotherapy for effective and well-tolerated in vivo delivery of immunomodulatory proteins.
引用
收藏
页码:769 / 775
页数:6
相关论文
共 50 条
  • [1] Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth
    Loeffler, Markus
    Le'Negrate, Gaelle
    Krajewska, Maryla
    Reed, John C.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (05) : 769 - 775
  • [2] Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth
    Loeffler, Markus
    Le'Negrate, Gaelle
    Krajewska, Maryla
    Reed, John C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) : 12879 - 12883
  • [3] CCL21 Programs Immune Activity in Tumor Microenvironment
    Sharma, Sherven
    Kadam, Pournima
    Dubinett, Steven
    TUMOR MICROENVIRONMENT: THE ROLE OF CHEMOKINES, PT A, 2020, 1231 : 67 - 78
  • [4] Intratumoral CCL21 and checkpoint blockade cooperatively inhibit NSCLC tumor growth in vivo to a greater extent than either monotherapy alone
    Salehi-rad, Ramin
    Walser, Tonya C.
    Yakobian, Natalie
    Park, Stacy J.
    Lee, Mi-Heon
    Lee, Jay Moon
    Sharma, Sherven
    Dubinett, Steven M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S41 - S41
  • [5] GENE THERAPY: CCL21 (SLC) INHIBITS PRIMARY PROSTATE TUMOR GROWTH AND METASTASES
    Yousefieh, Nazita
    Hahto, Suzanne
    Ciavarra, Richard Peter
    FASEB JOURNAL, 2008, 22
  • [6] Regulated Expression of CCL21 in the Prostate Tumor Microenvironment Inhibits Tumor Growth and Metastasis in an Orthotopic Model of Prostate Cancer
    Yousefieh, Nazita
    Hahto, Suzanne M.
    Stephens, Amber L.
    Ciavarra, Richard P.
    CANCER MICROENVIRONMENT, 2009, 2 (01) : 59 - 67
  • [7] Application of genetically engineered Salmonella typhimurium as tumor targeting agents
    Hong, Yeongjin
    Park, Seung-Hwan
    Kwon, Seong Young
    Min, Jung-Joon
    2013 13TH INTERNATIONAL CONFERENCE ON CONTROL, AUTOMATION AND SYSTEMS (ICCAS 2013), 2013, : 1504 - 1507
  • [8] Genetically engineered Salmonella typhimurium for targeted imaging of brain tumor
    Kang, Sae-Ryung
    Jiang, Sheng-Nan
    Min, Jung-Joon
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [9] Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer
    Liu, Xiande
    Jiang, Shengnan
    Piao, Linghua
    Yuan, Feng
    EXPERIMENTAL ANIMALS, 2016, 65 (04) : 413 - 418
  • [10] Fusion of CCL21 Non-Migratory Active Breast Epithelial and Breast Cancer Cells Give Rise to CCL21 Migratory Active Tumor Hybrid Cell Lines
    Berndt, Benjamin
    Haverkampf, Sonja
    Reith, Georg
    Keil, Silvia
    Niggemann, Bernd
    Zaenker, Kurt S.
    Dittmar, Thomas
    PLOS ONE, 2013, 8 (05):